NO954778L - Ekspresjon av urokinase plasminogen aktivator inhibitorer - Google Patents

Ekspresjon av urokinase plasminogen aktivator inhibitorer

Info

Publication number
NO954778L
NO954778L NO954778A NO954778A NO954778L NO 954778 L NO954778 L NO 954778L NO 954778 A NO954778 A NO 954778A NO 954778 A NO954778 A NO 954778A NO 954778 L NO954778 L NO 954778L
Authority
NO
Norway
Prior art keywords
expression
plasminogen activator
urokinase plasminogen
activator inhibitors
inhibitors
Prior art date
Application number
NO954778A
Other languages
English (en)
Norwegian (no)
Other versions
NO954778D0 (no
Inventor
Steven Rosenberg
Jennifer R Stratton-Thomas
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO954778D0 publication Critical patent/NO954778D0/no
Publication of NO954778L publication Critical patent/NO954778L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO954778A 1993-06-01 1995-11-24 Ekspresjon av urokinase plasminogen aktivator inhibitorer NO954778L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7015393A 1993-06-01 1993-06-01
PCT/US1994/005669 WO1994028145A2 (fr) 1993-06-01 1994-05-19 Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene

Publications (2)

Publication Number Publication Date
NO954778D0 NO954778D0 (no) 1995-11-24
NO954778L true NO954778L (no) 1995-11-24

Family

ID=22093474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954778A NO954778L (no) 1993-06-01 1995-11-24 Ekspresjon av urokinase plasminogen aktivator inhibitorer

Country Status (12)

Country Link
US (1) US6268341B1 (fr)
EP (1) EP0802983B1 (fr)
JP (1) JPH08508172A (fr)
KR (1) KR960702522A (fr)
AT (1) ATE239085T1 (fr)
AU (1) AU7137994A (fr)
CA (1) CA2162855A1 (fr)
DE (1) DE69432608T2 (fr)
FI (1) FI955721L (fr)
NO (1) NO954778L (fr)
NZ (1) NZ268470A (fr)
WO (1) WO1994028145A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
WO1994028145A2 (fr) 1993-06-01 1994-12-08 Chiron Corporation Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
JP2001520200A (ja) * 1997-10-17 2001-10-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウロキナーゼタイプのプラスミノーゲン活性化因子の内在化および分解を促進するための組成物および方法
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
DE69921102T2 (de) * 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
CA2483265A1 (fr) * 2002-04-25 2003-11-06 Clyde L. Schultz Systeme d'administration d'un facteur de croissance servant a la cicatrisation de plaies et a la prevention d'inflammations et de maladies
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2020140101A1 (fr) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Polypeptides activateurs de plasminogène de type urokinase modifiés et leurs procédés d'utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112755A (en) 1982-04-15 1992-05-12 Genentech, Inc. Preparation of functional human urokinase proteins
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4791068A (en) 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
CA1290267C (fr) 1985-04-15 1991-10-08 Lorin K. Johnson Proteine anti-inflammatoire inhibitrice de la phospholipase humaine
US5219569A (en) 1985-04-22 1993-06-15 Genentech, Inc. Protease resistant urokinase
EP0299053A1 (fr) 1987-01-30 1989-01-18 American Home Products Corporation Activateurs du plasminogene du facteur de croissance des-epidermique
US4835255A (en) 1987-03-26 1989-05-30 Yale University T-cell membrane protein
US4999194A (en) 1988-01-14 1991-03-12 Collaborative Research, Inc. Two-chain urokinase plasminogen activators for treatment of thrombotic disease
DK182289D0 (da) 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
DE69133049T2 (de) * 1990-10-18 2003-01-02 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Antikörper gegen den urokinaserezeptor und ihre verwendung
JPH0595786A (ja) 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
US5340833A (en) 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
WO1994028014A2 (fr) * 1993-05-28 1994-12-08 Chiron Corporation Peptides inhibiteurs de l'activite des recepteurs d'urokinase
WO1994028145A2 (fr) 1993-06-01 1994-12-08 Chiron Corporation Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene

Also Published As

Publication number Publication date
NZ268470A (en) 1997-09-22
FI955721A7 (fi) 1995-11-27
AU7137994A (en) 1994-12-20
NO954778D0 (no) 1995-11-24
DE69432608D1 (de) 2003-06-12
FI955721A0 (fi) 1995-11-27
EP0802983B1 (fr) 2003-05-02
EP0802983A2 (fr) 1997-10-29
ATE239085T1 (de) 2003-05-15
WO1994028145A3 (fr) 1995-10-19
CA2162855A1 (fr) 1994-12-08
DE69432608T2 (de) 2004-02-26
WO1994028145A2 (fr) 1994-12-08
FI955721L (fi) 1995-11-27
US6268341B1 (en) 2001-07-31
KR960702522A (ko) 1996-04-27
JPH08508172A (ja) 1996-09-03

Similar Documents

Publication Publication Date Title
WO1994028145A3 (fr) Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene
HUT63419A (en) Process for producing mercaptoacetamide derivatives of pyrrolo-, pyrido- and oxazinobenzazepine having encephalinase- and angiotensin-converting enzyme-inhibiting activity
AU2959995A (en) Stereochemical wortmannin derivatives
ATE47711T1 (de) Biologisch aktive verbindung mit anti-prolyl endopeptidasewirkung.
MX7113E (es) Procedimiento para aislar composiciones que contienen fibronectina,a partir de un crioprecipitado de plasma sanguineo
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
AU5846494A (en) Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
AU6458396A (en) Phosphorous-containing cysteine and serine protease inhibitors
DK0672115T3 (da) Fremgangsmåde til kloningsdyrkning af Streptococcus pneumoniae
GR78987B (fr)
AU1861588A (en) A method for the determination of the activity of serine proteases or serine protease inhibitors
EA199800200A1 (ru) Ингибиторы пролилэндопептидазы
GR3035645T3 (en) Process for making hiv protease inhibitors
EA199800468A1 (ru) 25-гидрокси-16-ен-26,27-бисгомохолекальциферолы
DE69018361D1 (de) Phosphorylierte plasminogenaktivatoren.
ATE89550T1 (de) Phenylsulfon-derivate.
NO891713D0 (no) Monoklonale antistoffer til vevplasminogenaktivator (t-pa)
AR018304A2 (es) Acido clavulanico y composicion que lo contiene
FI940334L (fi) Pikakuivahiiva
EA199800027A1 (ru) СПОСОБ СИНТЕЗА БЕНЗО[b]ТИОФЕНОВ
NO931629L (no) Rensing av plasminogen-aktivator-hemmer 2 ved immunaffinitetskromatografi
ES2146607T3 (es) Mezcla proteolitica que contiene escarasa y metodo de aislar la misma.
AU7378491A (en) Haloethyl-substituted steroidal enzyme inhibitors
AU2183788A (en) A process for obtaining higher yields of unaggregated tissue plasminogen activator from cell culture
GEP20022799B (en) ) Intermediates for Making HIV-Protease Inhibitors and Methods of Making HIV- Protease Inhibitors